Unione Europea - italiano - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - farmaci usati nel diabete - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

teva b.v. - dapagliflozin - dapagliflozin

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

krka d.d. novo mesto - dapagliflozin - dapagliflozin

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - dapagliflozinum - compresse rivestite con film - dapagliflozinum 5 mg dapagliflozinum propandiolum monohydricum 6.15 mg, cellulosum microcristallinum, lactosum 25 mg, crospovidonum, silice colloidalis hydrica, magnesio stearas, Überzug: poli(alcole vinylicus), e 171, macrogolum 3350, talco, e 172 (giallo), per compresso haze. - diabetes typ-2, herzinsuffizienz, chronische nierenerkrankung - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - dapagliflozinum - compresse rivestite con film - dapagliflozinum 10 mg a dapagliflozinum propandiolum monohydricum 12.30 mg, cellulosum microcristallinum, lactosum 50 mg, crospovidonum, silice colloidalis anhydrica, magnesio stearas, Überzug: poli(alcole vinylicus), e 171, macrogolum 3350, talco, e 172 (giallo), per compresso haze. - diabetes typ-2, herzinsuffizienz, chronische nierenerkrankung - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - dapagliflozinum, saxagliptinum - compresse rivestite con film - dapagliflozinum 10 mg ut dapagliflozinum propandiolum monohydricum, saxagliptinum 5 mg ut saxagliptini hydrochloridum, cellulosum microcristallinum, lactosum 40 mg, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidum hydrochloridum, natrii hydroxidum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: e 132, lacca, pro compresso obducto corresp. natrium max. 0.91 mg. - antidiabetico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - metformini hydrochloridum, dapagliflozinum - compresse rivestite con film - metformini hydrochloridum 500 mg, dapagliflozinum 5 mg ut dapagliflozinum propandiolum monohydricum, carmellosum natricum corresp. natrium 4.77 mg, hypromellosum, cellulosum microcristallinum, silica colloidalis hydrica, magnesii stearas, lactosum 48.00 mg, crospovidonum, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 110 0.69 mg, e 171, pro compresso obducto. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - metformini hydrochloridum, dapagliflozinum - compresse rivestite con film - metformini hydrochloridum 500 mg, dapagliflozinum 10 mg ut dapagliflozinum propandiolum monohydricum, carmellosum natricum corresp. natrium 4.77 mg, hypromellosum, cellulosum microcristallinum, silica colloidalis hydrica, magnesii stearas, lactosum 48.00 mg, crospovidonum, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (rubrum), pro compresso obducto. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - metformini hydrochloridum, dapagliflozinum - compresse rivestite con film - metformini hydrochloridum 1000 mg, dapagliflozinum 5 mg ut dapagliflozinum propandiolum monohydricum, carmellosum natricum corresp. natrium 4.75 mg, hypromellosum, cellulosum microcristallinum, silica colloidalis hydrica, magnesii stearas, lactosum 48.00 mg, crospovidonum, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (rubrum), pro compresso obducto. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - metformini hydrochloridum, dapagliflozinum - compresse rivestite con film - metformini hydrochloridum 1000 mg, dapagliflozinum 10 mg ut dapagliflozinum propandiolum monohydricum, carmellosum natricum corresp. natrium 4.75 mg, hypromellosum, silica colloidalis hydrica, magnesii stearas, cellulosum microcristallinum, lactosum 48.00 mg, crospovidonum, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - farmaco antidiabetico orale - synthetika